Literature DB >> 1722937

Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted.

A L Brown1, M J Francis, G Z Hastings, N R Parry, P V Barnett, D J Rowlands, B E Clarke.   

Abstract

The presentation of heterologous amino acid sequences on the surface of hepatitis B core antigen (HBcAg) particles has been studied using a defined linear neutralization site from human rhinovirus (HRV). Previous work has shown that fusion particles, in which the HRV peptide sequence is linked to the amino terminus of the HBcAg protein, induce excellent immune responses in experimental animals. Using predictive models of HBcAg particulate structure and the approximate location of the major immunogenic regions we have designed and constructed bacterial expression vectors which direct synthesis of chimeric particles in which heterologous sequences are presented within an immunodominant area on the particle. Immunological responses to the heterologous peptide sequence are improved by at least tenfold when compared with amino terminal fusions of the same peptide sequence to HBcAg. Moreover, the restriction placed on the heterologous peptide by its linkage at both ends within the HBcAg protein results in a more constrained structure. In the case of the rhinovirus peptide sequence this results in an antigenic conformation more closely resembling that on the native virus particle. Such a system lends itself well as a general approach to the induction of high titre antibodies against defined epitopes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722937     DOI: 10.1016/0264-410x(91)90248-5

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  13 in total

1.  Expression and immunoreactivity of an epitope of HCV in a foreign epitope presenting system.

Authors:  Mei Peng; Chang-Bai Dai; Yuan-Ding Chen
Journal:  World J Gastroenterol       Date:  2005-06-14       Impact factor: 5.742

2.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

3.  Chimeric hepatitis B virus core particles as probes for studying peptide-integrin interactions.

Authors:  M A Chambers; G Dougan; J Newman; F Brown; J Crowther; A P Mould; M J Humphries; M J Francis; B Clarke; A L Brown; D Rowlands
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  Chimeric hepatitis B virus core particles with parts or copies of the hepatitis C virus core protein.

Authors:  A Yoshikawa; T Tanaka; Y Hoshi; N Kato; K Tachibana; H Iizuka; A Machida; H Okamoto; M Yamasaki; Y Miyakawa
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

Review 5.  Use of hepadnavirus core proteins as vaccine platforms.

Authors:  David C Whitacre; Byung O Lee; David R Milich
Journal:  Expert Rev Vaccines       Date:  2009-11       Impact factor: 5.217

6.  Localization of an immunodominant domain on baculovirus-produced parvovirus B19 capsids: correlation to a major surface region on the native virus particle.

Authors:  C S Brown; T Jensen; R H Meloen; W Puijk; K Sugamura; H Sato; W J Spaan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

7.  Structures of hepatitis B virus cores presenting a model epitope and their complexes with antibodies.

Authors:  A M Roseman; O Borschukova; J A Berriman; S A Wynne; P Pumpens; R A Crowther
Journal:  J Mol Biol       Date:  2012-06-28       Impact factor: 5.469

8.  Tandem fusion of hepatitis B core antigen allows assembly of virus-like particles in bacteria and plants with enhanced capacity to accommodate foreign proteins.

Authors:  Hadrien Peyret; Annick Gehin; Eva C Thuenemann; Donatienne Blond; Aadil El Turabi; Lucy Beales; Dean Clarke; Robert J C Gilbert; Elizabeth E Fry; David I Stuart; Kris Holmes; Nicola J Stonehouse; Mike Whelan; William Rosenberg; George P Lomonossoff; David J Rowlands
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

9.  Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice.

Authors:  Ming Yang; Huafang Lai; Haiyan Sun; Qiang Chen
Journal:  Sci Rep       Date:  2017-08-09       Impact factor: 4.379

Review 10.  Use of macromolecular assemblies as expression systems for peptides and synthetic vaccines.

Authors:  G P Lomonossoff; J E Johnson
Journal:  Curr Opin Struct Biol       Date:  1996-04       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.